MeiraGTx Holdings PLCNASDAQ:MGTX
- LAST PRICE5.7100
- TODAY'S CHANGE (%)0.0300 (0.5282%)
- Bid / Lots5.6700/ 1
- Ask / Lots5.7500/ 1
- Open / Previous Close5.7400 / 5.6800
- Day Range
- 52 Week Range
- Volume68,724
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MGTX |
|---|---|---|
| 09:32 ET | 8952 | 5.705 |
| 09:34 ET | 200 | 5.695 |
| 09:36 ET | 635 | 5.68 |
| 09:38 ET | 100 | 5.7319 |
| 09:39 ET | 629 | 5.69 |
| 09:43 ET | 2546 | 5.71 |
| 09:45 ET | 400 | 5.715 |
| 09:48 ET | 100 | 5.71 |
| 09:52 ET | 200 | 5.71 |
| 09:57 ET | 100 | 5.74 |
| 10:01 ET | 300 | 5.7 |
| 10:10 ET | 100 | 5.7 |
| 10:12 ET | 300 | 5.68 |
| 10:28 ET | 200 | 5.7 |
| 10:35 ET | 175 | 5.68 |
| 10:46 ET | 1200 | 5.7 |
| 10:50 ET | 100 | 5.72 |
| 10:51 ET | 100 | 5.7 |
| 10:55 ET | 100 | 5.72 |
| 10:57 ET | 100 | 5.72 |
| 11:00 ET | 700 | 5.7 |
| 11:02 ET | 100 | 5.75 |
| 11:08 ET | 200 | 5.75 |
| 11:09 ET | 200 | 5.75 |
| 11:11 ET | 700 | 5.73 |
| 11:22 ET | 200 | 5.78 |
| 11:24 ET | 100 | 5.76 |
| 11:29 ET | 100 | 5.79 |
| 11:33 ET | 100 | 5.765 |
| 11:38 ET | 200 | 5.75 |
| 11:42 ET | 100 | 5.765 |
| 11:47 ET | 1110 | 5.7 |
| 12:20 ET | 300 | 5.71 |
| 12:21 ET | 100 | 5.71 |
| 12:23 ET | 100 | 5.72 |
| 12:25 ET | 3077 | 5.71 |
| 12:34 ET | 100 | 5.72 |
| 12:36 ET | 845 | 5.73 |
| 12:38 ET | 400 | 5.7 |
| 12:43 ET | 146 | 5.68 |
| 12:48 ET | 100 | 5.705 |
| 12:56 ET | 100 | 5.7 |
| 01:12 ET | 100 | 5.7 |
| 01:37 ET | 815 | 5.67 |
| 01:44 ET | 197 | 5.6509 |
| 01:51 ET | 100 | 5.68 |
| 01:53 ET | 1800 | 5.675 |
| 02:00 ET | 100 | 5.7 |
| 02:06 ET | 100 | 5.7 |
| 02:13 ET | 400 | 5.7 |
| 02:26 ET | 100 | 5.68 |
| 02:31 ET | 250 | 5.69 |
| 02:38 ET | 1800 | 5.68 |
| 02:45 ET | 200 | 5.7 |
| 03:02 ET | 100 | 5.7 |
| 03:20 ET | 432 | 5.69 |
| 03:27 ET | 100 | 5.67 |
| 03:30 ET | 262 | 5.67 |
| 03:34 ET | 100 | 5.675 |
| 03:36 ET | 100 | 5.68 |
| 03:38 ET | 100 | 5.68 |
| 03:41 ET | 1315 | 5.69 |
| 03:43 ET | 400 | 5.7 |
| 03:45 ET | 600 | 5.7 |
| 03:48 ET | 200 | 5.7 |
| 03:50 ET | 700 | 5.705 |
| 03:52 ET | 600 | 5.72 |
| 03:56 ET | 700 | 5.71 |
| 03:59 ET | 12016 | 5.71 |
May 9, 2024
*DJ MeiraGTx Holdings 1Q Loss/Shr 32c >MGTX, from 8:00AM ET on Thursday May 09, 2024 by Dow Jones
8:00AM ET on Thursday May 09, 2024 by Dow JonesMeiraGTx Reports First Quarter 2024 Financial and Operational Results, from 8:00AM ET on Thursday May 09, 2024 by Dow Jones
8:00AM ET on Thursday May 09, 2024 by Dow Jones
Apr 24, 2024
MeiraGTx to Participate in Upcoming Investor Conferences, from 4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 18, 2024
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference, from 4:30PM ET on Thursday Apr 18, 2024 by Dow Jones
4:30PM ET on Thursday Apr 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MeiraGTx Holdings PLC | 365.3M | -4.5x | --- |
AC Immune SA | 338.3M | -4.5x | --- |
Shattuck Labs Inc | 372.8M | -4.1x | --- |
Q32 Bio Inc | 370.2M | -1.2x | --- |
C4 Therapeutics Inc | 410.8M | -2.4x | --- |
Nautilus Biotechnology Inc | 365.8M | -5.5x | --- |
Company Information
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Contact Information
- Headquarters
- 450 E 29th St Fl 15NEW YORK, NY, United States 10016-8367
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Keith Harris
- President, Chief Executive Officer, Director
- Alexandria Forbes
- Chief Financial Officer, Chief Operating Officer
- Richard Giroux
- General Counsel, Secretary
- Robert Wollin
- Chief Development Officer
- Stuart Naylor
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $365.3M |
|---|---|
Revenue (TTM) | $11.4M |
Shares Outstanding | 64.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-1.27 |
Book Value | $2.17 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | 32.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
